## **U** NOVARTIS

## FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia

Nov 01, 2021

**Source URL:** https://qa1.novartis.us/news/media-releases/fda-approves-novartis-scemblix-asciminib-novelmechanism-action-treatment-chronic-myeloid-leukemia-0

## List of links present in page

1. https://qa1.novartis.us/news/media-releases/fda-approves-novartis-scemblix-asciminib-novel-mechanism-action-treatment-chronic-myeloid-leukemia-0